-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

677 Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond
Hematology Disease Topics & Pathways:
Combination therapy, Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Diseases, Immunotherapy, Biological therapies, Treatment Considerations, Lymphoid Malignancies
Sunday, December 8, 2024: 5:30 PM

Luciano J. Costa, MD, PhD1, Fredrik Schjesvold, MD, PhD2,3, Rakesh Popat, MBBS, PhD4, David Siegel5*, Saad Z. Usmani, MD6, Syed Abbas Ali7, Michael P. Chu, MD8, Monique A. Hartley-Brown, MD9, Nizar J. Bahlis10*, Albert Oriol11*, Joaquín Martínez Lopez12*, Enrique M. Ocio13, Karthik Ramasamy14, Donna Reece, MD15, Emma Searle16*, Allison Gaudy17*, Antonina Kurtova17*, Wen Zhang17*, Rafael Sarmiento18*, August Dietrich19, Jessica Katz17, Michael Pourdehnad, MD17 and Paul G. Richardson9

1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
2Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
3Department of Haematology, Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
4NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom
5John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
7Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
8Department of Oncology, University of Alberta, Edmonton, AB, Canada
9Dana-Farber Cancer Institute, Boston, MA
10Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
11Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
12Department of Hematology, Hospital 12 de Octubre, Complutense University, H12O-CNIO Clinical Research Unit, CIBERONC, Madrid, Spain
13Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
14Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
15Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
16The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
17Bristol Myers Squibb, Princeton, NJ
18Bristol Myers Squibb, Center for Innovation and Translational Research Europe (CITRE), Seville, Spain
19Research and Development, Bristol Myers Squibb, Princeton, NJ

Introduction: MEZI, a novel, potent oral CELMoD™ agent, induces rapid and maximal degradation of Ikaros and Aiolos compared with immunomodulatory drugs (IMiDs®), resulting in direct tumoricidal and immunomodulatory effects in myeloma cells. The CA057-003 phase 1/2 trial (NCT05372354) is evaluating all-oral, novel-novel targeted triplet combination regimens using a MEZI plus dexamethasone (DEX) (MEZId) backbone in patients (pts) with RRMM. The third agent in each combination intervenes on a key oncogenic pathway identified by The Myeloma Genome Project to be upregulated in RRMM: the EZH2 inhibitor tazemetostat (TAZ) for PRC2 complex dysregulation, the BET inhibitor BMS-986158 for CKS1b (located on Chr 1q) amplification, and the MEK inhibitor trametinib (TRAM) for RAS-RAF-MEK-ERK activation. Here we report preliminary results from the CA057-003 dose-finding cohorts of MEZId combined with TAZ, BMS-986158, or TRAM in pts with RRMM.

Methods: Eligible pts had RRMM with documented progressive disease (PD) during or after the last regimen, ECOG performance status score ≤1, and were intolerant to or ineligible for all available established therapies. Oral MEZI was given daily (QD) at escalating doses of 0.3, 0.6, or 1.0 mg on days (D)1–21 of each 28-D cycle with 40 mg (20 mg if ≥75 y of age) weekly DEX plus 800 mg twice daily oral TAZ on D1–28; 2 or 3 mg QD oral BMS-986158 5D-on-2D-off D1–14; or 1.5 or 2 mg QD oral TRAM on D1–21. Primary objectives included defining the recommended phase 2 dose and dosing schedule, and evaluating safety. Secondary objectives included efficacy and pharmacokinetics. There was no biomarker screening.

Results: As of May 8, 2024, 14 pts received MEZId + TAZ, 16 MEZId + BMS-986158, and 15 MEZId + TRAM. Across all cohorts, median (range) age was 63 (37–83) y and median time since initial diagnosis was 7.5 (2.0–18.4) y. Eight (18%) pts were Black/African American, 35 (78%) White, and race was not collected/unknown (NA) in 2 (4%); 6 (13%) were Hispanic/Latino and 36 (80%) were not (NA = 3 [7%] pts); 56% were in the United States. Extramedullary plasmacytomas were present in 16 (36%) pts. The median number of prior antimyeloma regimens was 5 (2–20). Prior therapies included autologous stem cell transplantation (78%), IMiD agents (100%), proteasome inhibitors (PIs; 100%), anti-CD38 monoclonal antibodies (mAbs; 100%), and T cell-redirecting therapy (58%); 82% had triple-class refractory disease (to an IMiD agent, PI, and anti-CD38 mAb).

At data cutoff, 7 (50%) pts continued on treatment in the MEZId + TAZ cohort, 8 (50%) in the MEZId + BMS-986158 cohort, and 10 (67%) in the MEZId + TRAM cohort. The main reason for discontinuation in all 3 cohorts was PD. Median follow-up was 4.1 (1.0–11.0) mo (MEZId + TAZ), 2.9 (1.0–6.5) mo (MEZId + BMS-986158), and 3.6 (0–10.6) mo (MEZId + TRAM).

The most frequent grade (Gr) 3/4 treatment-emergent adverse event (TEAE) across all 3 cohorts was neutropenia (43–73%); Gr 3/4 non-hematologic TEAEs were low or absent. Three pts had dose-limiting toxicities (1 with 0.3 mg MEZId + BMS-986158, 1 with 1.0 mg MEZId + BMS-986158, and 1 with 1.0 mg MEZId + TRAM).

In the efficacy-evaluable population, overall response rate (≥ partial response [PR]) was 54% (7/13 pts) with MEZId + TAZ; 36% (5/14) with MEZId + BMS-986158; and 92% (11/12) with MEZId + TRAM. In the MEZId + TAZ and MEZId + BMS-986158 cohorts, deeper responses (≥ very good PR), including 1 stringent complete response (sCR) with MEZId + TAZ, were observed with 1.0 mg MEZI, and in the MEZId + TRAM cohort with ≥0.6 mg MEZI (including 1 sCR), and 100% (5/5 pts) at 1.0 mg MEZI were ongoing responses with this combination.

Exposures increased in a dose-linear manner over the dose range and were consistent across treatment cohorts, demonstrating no drug-drug interaction between MEZI and novel therapeutic agents. MEZI remained pharmacodynamically active, inducing Ikaros/Aiolos degradation and B-cell reduction with all combination agents at all dose levels, with the greatest effect observed at MEZI 1.0 mg.

Conclusions: MEZId combined with the novel therapeutic agents TAZ, BMS-986158, or TRAM showed promising efficacy and a manageable safety profile in patients with RRMM. No new safety signals were identified, with neutropenia being the most common Gr 3/4 TEAE in all 3 cohorts. These results provide a rationale for further exploration of these novel all-oral combinations. Accrual continues and updated results will be presented at the meeting.

Disclosures: Costa: Janssen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Caribou: Research Funding; Genentech, Inc.: Consultancy, Honoraria, Research Funding; Adaptive biotechnoligies: Honoraria; Pfizer: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria. Schjesvold: Takeda: Consultancy, Other: Honoraria for lectures and educational material; Amgen: Other: Honoraria for lectures and educational material; Targovax: Research Funding; Celgene: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; AbbVie: Consultancy, Other: Honoraria for lectures and educational material; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Other: Honoraria for lectures and educational material; GSK: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; SkylineDx: Other: Honoraria for lectures and educational material; Novartis: Other: Honoraria for lectures and educational material; Daiichi Sankyo: Other: Honoraria for lectures and educational material; Janssen-Cilag: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Oncopeptides: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Pfizer: Other: Honoraria for lectures and educational material; Schain: Other: Honoraria for lectures and educational material; Skylite: Other: Honoraria for lectures and educational material. Popat: Pfizer: Honoraria, Research Funding, Speakers Bureau; GSK: Honoraria, Research Funding; Sanofi: Honoraria; Janssen: Honoraria, Speakers Bureau; Abbvie: Honoraria; BMS: Honoraria. Usmani: Bristol-Myers Squibb: Consultancy, Research Funding; Array Biopharma: Research Funding; Gracell: Consultancy; Abbvie: Consultancy, Research Funding; SkylineDX: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Pharmacyclics: Research Funding; SeaGen: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; SecuraBio: Consultancy; Gilead: Research Funding; Oncopeptides: Consultancy; Pfizer: Consultancy; Sanofi: Consultancy, Research Funding; Bristol-Myers Squibb - Celgene:: Consultancy, Research Funding; EdoPharma: Consultancy; Takeda: Consultancy, Research Funding; TeneoBio: Consultancy; GSK: Consultancy, Research Funding; Merck: Research Funding; Genentech: Consultancy; Bristol-Myers Squibb - Celgene: Consultancy, Research Funding; Johnson & Johnson - Janssen: Consultancy, Research Funding. Ali: Bristol Myers Squibb: Consultancy, Research Funding; Pfizer/IMF: Research Funding; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees. Chu: Pfizer: Honoraria; Janssen: Honoraria; AstraZeneca: Honoraria; Amgen: Honoraria; Kite/Gilead: Honoraria; Sanofi: Honoraria; Amgen: Consultancy; BMS: Honoraria. Hartley-Brown: Sanofi: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria, Research Funding; Multiple Myeloma Research Foundation: Consultancy, Honoraria, Research Funding; Cancer Care: Consultancy, Honoraria. Bahlis: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Karyopharm Therapeutics, Kyte, Novartis, Pfizer, Roche, Sanofi, Takeda: Consultancy; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Genentech, Karyopharm Therapeutics, Kyte, Novartis, Pfizer, Roche, Sanofi, Takeda: Membership on an entity's Board of Directors or advisory committees; Janssen, Pfizer: Research Funding; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Genentech, Karyopharm Therapeutics, Kyte, Novartis, Pfizer, Roche, Sanofi, Takeda: Honoraria. Oriol: Sanofi: Honoraria, Speakers Bureau; Pfizer, Amgen, Oncopeptides: Honoraria; GSK: Honoraria, Speakers Bureau; Bristol Myers Squibb/Celgene: Honoraria, Speakers Bureau; Johnson & Johnson, Janssen: Honoraria, Speakers Bureau. Lopez: BMS, Pfizer, Janssen, Amgen, Roche, Kite: Consultancy; BMS, Pfizer, Janssen, Amgen, Roche, Kite: Honoraria; Pfizer, Janssen, Incity: Research Funding. Ocio: Takeda: Consultancy, Honoraria; Regeneron: Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria, Research Funding; Menarini: Consultancy, Honoraria; AstraZeneca: Consultancy; Janssen: Consultancy, Honoraria, Speakers Bureau; Amgen: Honoraria; GSK: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria. Ramasamy: Bristol-Myers Squibb: Other: Travel; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Recordati: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Menarini: Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees; Johnson & Johnson - Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb - Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees, Research Funding. Reece: Janssen, BMS, Sanofi, ORIC, Princess Margaret Cancer Centre: Other: Grants; BMS, Janssen, Sanofi, GSK, Pfizer: Consultancy; BMS, Janssen, Takeda, Pfizer: Honoraria; BMS: Membership on an entity's Board of Directors or advisory committees. Searle: DarkBlue Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Jazz: Speakers Bureau; AbbVie: Honoraria, Speakers Bureau; Beigene: Honoraria; Nurix: Honoraria. Gaudy: BMS: Current Employment, Current equity holder in publicly-traded company. Kurtova: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Zhang: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Sarmiento: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Dietrich: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Katz: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Pourdehnad: Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Richardson: Oncopeptides: Research Funding; Celgene/Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron, Sanofi: Consultancy.

*signifies non-member of ASH